Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

Study Overview
=================
Brief Summary
-----------------
The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.

Official Title
-----------------
Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention

Conditions
-----------------
Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Aged, Percutaneous Coronary Intervention

Intervention / Treatment
-----------------
* Drug: Ticagrelor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age≥75 years old; Treated with PCI (limited to stent implantation) ; Survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at discharge; Exclusion Criteria: Coronary artery bypass graft (CABG) or only drug conservative treatment during hospitalization; Concurrent use of oral anticoagulants; Inability to tolerate long-term antiplatelet therapy, such as active bleeding and a bleeding tendency; Acute infectious diseases; Cognitive impairment; Declined re-examination.

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| The Elderly Undergoing Percutaneous Coronary Intervention<br>Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge. | Drug: Ticagrelor<br>* Patients were survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.<br>* Other names: Clopidogrel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Types 2, 3, and 5 bleeding, as defined by the Bleeding Academic Research Consortium | The primary safety endpoint | 12 months | 
| Combined major adverse cardiovascular and cerebrovascular events (MACCEs), including all-cause mortality, myocardial infarction, ischemic stroke, and any revascularization. | The primary efficacy endpoint | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality |  | 12 months | 
| Myocardial infarction |  | 12 months | 
| Revascularization |  | 12 months | 
| Ischemic stroke |  | 12 months | 
| Incidence of BARC3 and 5 bleeding |  | 12 months | 
| Incidence of major and minor bleeding defined by the PLATO study |  | 12 months | 
| Incidence of major and minor bleeding defined by the TIMI study |  | 12 months | 
| Occurrence of any bleeding |  | 12 months |